What exhibit did Allarity Therapeutics (ALLR) include with this 8-K related to the conference?

Allarity Therapeutics included Exhibit 99.1, a press release dated September 17, 2025. This release provides more information on CEO Thomas Jensen’s invitation to present at the Biomarkers & Precision Medicine 2025 conference in London organized by Oxford Global.

Allarity Therapeutics CEO to Present in London

Allarity Therapeutics, Inc. reported that its CEO, Thomas Jensen, has been invited to present at the Biomarkers & Precision Medicine 2025 conference in London, organized by Oxford Global.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Allarity Therapeutics, Inc. reported that its CEO, Thomas Jensen, has been invited to present at the Biomarkers & Precision Medicine 2025 conference in London, organized by Oxford Global. The company also furnished a related press release as an exhibit, providing additional details on this conference participation.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Allarity Therapeutics (ALLR) announce in this 8-K filing?

Allarity Therapeutics announced that CEO Thomas Jensen has been invited to present at the Biomarkers & Precision Medicine 2025 conference in London. The company attached a press release as an exhibit providing further details on the upcoming presentation and event context.

Who from Allarity Therapeutics (ALLR) will present at the Biomarkers & Precision Medicine 2025 conference?

CEO Thomas Jensen will present at the Biomarkers & Precision Medicine 2025 conference in London. His participation highlights the company’s involvement in the precision medicine and biomarker field, as described in the accompanying press release filed as an exhibit to the report.

Where is the Biomarkers & Precision Medicine 2025 conference mentioned by Allarity Therapeutics (ALLR) being held?

The Biomarkers & Precision Medicine 2025 conference is being held in London. Allarity Therapeutics disclosed that its CEO, Thomas Jensen, has been invited to present there, and supplied a dedicated press release as an exhibit explaining this conference participation in more detail.

Does the Allarity Therapeutics (ALLR) 8-K describe any financial results or major transactions?

The 8-K focuses on CEO Thomas Jensen’s upcoming presentation at the Biomarkers & Precision Medicine 2025 conference. It does not describe financial results or major transactions, instead highlighting conference participation and attaching a related press release as Exhibit 99.1.

What is the main purpose of this Allarity Therapeutics (ALLR) 8-K filing?

The main purpose is to inform investors that CEO Thomas Jensen has been invited to present at the Biomarkers & Precision Medicine 2025 conference in London. The filing also formally records the related press release as an exhibit for regulatory and disclosure purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 09/19/2025 - 06:13 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 17, 2025

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41160		87-2147982
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

123 E Tarpon Ave,

Tarpon Springs, FL 34689

(Address of principal executive offices)

(401) 426-4664

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ALLR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 17, 2025, Allarity Therapeutics, Inc. (the “Company”) announced that its CEO, Mr. Thomas Jensen, has been invited to present at the upcoming Biomarkers & Precision Medicine 2025 conference in London, organized by Oxford Global. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release, dated September 17, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Allarity Therapeutics, Inc.

Date: September 19, 2025	By:	/s/ Thomas H. Jensen
		Thomas H. Jensen
		Chief Executive Officer

Source: View Original Filing on SEC EDGAR